Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03186118 · ClinicalTrials.gov registry record · Phase 1
Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia
A Phase 1 study of CD 19+ Acute Leukemia, sponsored by Seattle Children's Hospital.
- Active
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT03186118: Active Phase 1 study of CD 19+ Acute Leukemia, sponsored by Seattle Children's Hospital.
NCT03186118 is a Phase 1 study of CD 19+ Acute Leukemia that is active but no longer recruiting, run by Seattle Children's Hospital. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03186118, a Phase 1 study of CD 19+ Acute Leukemia, is active but no longer recruiting, sponsored by Seattle Children's Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients with relapsed or refractory CD 19+ leukemia who have achieved remission after CD19 CAR-T cell treatment sometimes relapse because the CD 19 CAR-T cells decrease in number over time. Study PLAT-03 will test whether administering T cell antigen presenting cells (T-APCs) at intervals following treatment with CAR-T cells improves CD 19 CAR-T cell persistence and reduces the incidence of leukemia relapse.
Primary Outcome
Type, frequency, severity, and duration of adverse events will be summarized
Conditions Studied
Interventions
- BIOLOGICAL T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC)
Study Locations (1)
Washington
- Seattle Children's Hospital - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-08-04 |
| Est. Completion | 2033-07 |
| Phase | Phase 1 |
What the registry record for NCT03186118 still lists
NCT03186118 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).
The record links to 1 condition, with CD 19+ Acute Leukemia appearing as the primary indexed condition, and to 1 intervention - of which T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC) is the first listed.
NCT03186118 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT03186118 about?
NCT03186118 is a clinical study titled "Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia". Patients with relapsed or refractory CD 19+ leukemia who have achieved remission after CD19 CAR-T cell treatment sometimes relapse because the CD 19 CAR-T cells decrease in number over time. Study PLAT-03 will test whether administering T cell antigen presenting cells (T-APCs) at intervals following...
What is the current status of trial NCT03186118?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2017-08-04. Estimated completion is 2033-07.
What conditions does trial NCT03186118 study?
This clinical trial studies the following conditions: CD 19+ Acute Leukemia.
What interventions are being tested in trial NCT03186118?
The interventions under investigation include: T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03186118?
This trial is sponsored by Seattle Children's Hospital, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03186118 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for CD 19+ Acute Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03186118's enrollment target sits among peer trials
30 1332nd of 2000 higher than 561 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI